Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vitamin D3 analogue ILX23-7553

A vitamin D3 analogue with potential antineoplastic activity. ILX23-7553 binds to and activates the vitamin D receptor, a cytoplasmic polypeptide expressed in normal vitamin D responsive tissues, but also overexpressed in certain cancers including hepatocellular carcinoma and pancreatic cancer. Mediated through vitamin D receptor, this agent induces cancer cell differentiation, inhibits cancer cell growth and induces apoptosis. In addition, ILX23-7553 may also induce growth arrest and apoptosis independent of vitamin D receptor activation through mechanisms that are not fully elucidated.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:16-23-D3
Code name:BXL 353
ILEX 23-7553
ILX 237553
ILX-237553
ILX23 7553
ILX23-7553
ILX237553
RO 237553
RO-237553
Ro23-7553
RO237553
Chemical structure:1,25-dihydroxy-16-ene-23-yne-cholecalciferol
9,10-secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol, (1alpha,3beta,5Z,7E)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search